These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32211773)

  • 1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function.
    Albrethsen J; Johannsen TH; Jørgensen N; Frederiksen H; Sennels HP; Jørgensen HL; Fahrenkrug J; Petersen JH; Linneberg A; Nordkap L; Bang AK; Andersson AM; Juul A
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32211773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Increases in Serum Insulin-like Factor 3 and Testosterone Determined by LC-MS/MS in Pubertal Danish Boys.
    Albrethsen J; Ljubicic ML; Juul A
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32761207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.
    Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J
    Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis.
    Bay K; Hartung S; Ivell R; Schumacher M; Jürgensen D; Jorgensen N; Holm M; Skakkebaek NE; Andersson AM
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3410-8. PubMed ID: 15755855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum INSL3 measured by LC-MS/MS in pubertal girls and in girls with precocious puberty during GnRH agonist treatment.
    Albrethsen J; Hagen CP; Juul A
    Front Endocrinol (Lausanne); 2024; 15():1404320. PubMed ID: 39010900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum.
    Albrethsen J; Frederiksen H; Andersson AM; Anand-Ivell R; Nordkap L; Bang AK; Jørgensen N; Juul A
    Clin Chem Lab Med; 2018 Oct; 56(11):1913-1920. PubMed ID: 29847312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression.
    Albrethsen J; Østergren PB; Norup PB; Sønksen J; Fode M; Kistorp C; Nordsborg NB; Solheim SA; Mørkeberg J; Main KM; Juul A
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2834-2839. PubMed ID: 37235781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity.
    Rasmussen JJ; Albrethsen J; Frandsen MN; Jørgensen N; Juul A; Kistorp C
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2664-e2672. PubMed ID: 33693710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acute hCG stimulation on serum INSL3 and 25-OH vitamin D in Klinefelter syndrome.
    Santi D; Ivell R; Anand-Ivell R; De Toni L; Fanelli F; Mezzullo M; Pelusi C; Pagotto U; Belli S; Granata ARM; Roli L; Rochira V; Trenti T; Ferlin A; Simoni M
    Andrology; 2020 Nov; 8(6):1720-1727. PubMed ID: 32593193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like factor 3 quantification by LC-MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome.
    Johannsen TH; Ljubicic ML; Young J; Trabado S; Petersen JH; Linneberg A; Albrethsen J; Juul A
    Endocrine; 2021 Mar; 71(3):578-585. PubMed ID: 33483888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of insulin-like factor 3, anti-Mullerian hormone, inhibin B, and testosterone during pubertal transition in healthy boys: a longitudinal pilot study.
    Johansen ML; Anand-Ivell R; Mouritsen A; Hagen CP; Mieritz MG; Søeborg T; Johannsen TH; Main KM; Andersson AM; Ivell R; Juul A
    Reproduction; 2014; 147(4):529-35. PubMed ID: 24459206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency.
    Medici C; Jørgensen N; Juul A; Albrethsen J; Kreiberg M; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2024 Feb; 22(1):e106-e112.e4. PubMed ID: 37673783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort.
    Anand-Ivell R; Heng K; Severn K; Antonio L; Bartfai G; Casanueva FF; Huhtaniemi IT; Giwercman A; Maggi M; O'Neill TW; Punab M; Rastrelli G; Slowikowska-Hilczer J; Tournoy J; Vanderschueren D; Wu FCW; Ivell R
    Andrology; 2022 Oct; 10(7):1328-1338. PubMed ID: 35770372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in serum insulin-like factor 3 during normal male puberty.
    Ferlin A; Garolla A; Rigon F; Rasi Caldogno L; Lenzi A; Foresta C
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3426-31. PubMed ID: 16804040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal insulin-like peptide-3 levels despite low testosterone in adult males with Prader-Willi syndrome: variations in Leydig cell function from infancy through adulthood.
    Hirsch HJ; Eldar-Geva T; Gross-Tsur V; Benarroch F; Roger M; Lahlou N
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E135-43. PubMed ID: 23150680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.
    Trabado S; Maione L; Bry-Gauillard H; Affres H; Salenave S; Sarfati J; Bouvattier C; Delemer B; Chanson P; Le Bouc Y; Brailly-Tabard S; Young J
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E268-75. PubMed ID: 24243640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INSL3: A Marker of Leydig Cell Function and Testis-Bone-Skeletal Muscle Network.
    Facondo P; Delbarba A; Maffezzoni F; Cappelli C; Ferlin A
    Protein Pept Lett; 2020; 27(12):1246-1252. PubMed ID: 32981493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression patterns of DLK1 and INSL3 identify stages of Leydig cell differentiation during normal development and in testicular pathologies, including testicular cancer and Klinefelter syndrome.
    Lottrup G; Nielsen JE; Maroun LL; Møller LM; Yassin M; Leffers H; Skakkebæk NE; Rajpert-De Meyts E
    Hum Reprod; 2014 Aug; 29(8):1637-50. PubMed ID: 24908673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold.
    Anand-Ivell R; Heng K; Antonio L; Bartfai G; Casanueva FF; Maggi M; O'Neill TW; Punab M; Rastrelli G; Slowikowska-Hilczer J; Tournoy J; Vanderschueren D; Wu FC; Huhtaniemi IT; Ivell R
    Aging Male; 2024 Dec; 27(1):2346322. PubMed ID: 38676285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A negative correlation between insulin-like peptide 3 and bisphenol A in human cord blood suggests an effect of endocrine disruptors on testicular descent during fetal development.
    Chevalier N; Brucker-Davis F; Lahlou N; Coquillard P; Pugeat M; Pacini P; Panaïa-Ferrari P; Wagner-Mahler K; Fénichel P
    Hum Reprod; 2015 Feb; 30(2):447-53. PubMed ID: 25527819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.